Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
03:55pm, Tuesday, 04'th Feb 2025
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advise
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
10:00am, Saturday, 01'st Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investo
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
KROS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Keros Therapeutics, Inc. Shareholders Who Lost Money
10:30am, Thursday, 30'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
08:00am, Thursday, 30'th Jan 2025
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Keros Therapeutics, Inc. (KROS)
10:30am, Wednesday, 29'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation
10:00am, Wednesday, 29'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
Keros Therapeutics, Inc. Being Investigated on Behalf of Keros Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
01:00pm, Tuesday, 28'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KRO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
12:55pm, Tuesday, 28'th Jan 2025
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advise
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect
10:00am, Tuesday, 28'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
08:15am, Tuesday, 28'th Jan 2025
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of t
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
